When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
April W. Armstrong, MD, MPH, of @KeckMedUSC, and Erin E. Boh, MD, PhD, of @TulaneMedicine, discuss the use of IL-23 and IL-17 inhibitors in #psoriaticdisease.
Erik F. Wang, James Yu, DO, MS, John E. Rubin, MD, and Rohan Jotwani, MD, of @WeillCornell, discuss #VirtualReality for pre-procedural #modeling and #practice.
This video provides a general overview of information based on recently published guidelines on vaccines for patients with rheumatic and musculoskeletal diseases from the American College of Rheumatology.…
This video from the National Kidney Foundation highlights the importance of maintaining the right amount of potassium in the body, as it is vital for the proper functioning…
Brian Shuch, MD, director of the UCLA Kidney Cancer Program, discusses considerations for partial or radical nephrectomy. Chronic kidney disease can lead to a loss of kidney function, which…
Brian Shuch, MD, director of the UCLA Kidney Cancer Program, discusses what to expect after a robotic-assisted partial nephrectomy. The procedure is performed using a da Vinci robot to…
